Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Verapamil is a non-dihydropyridine calcium channel blocker used primarily to treat hypertension (high blood pressure), angina pectoris (chest pain), and certain cardiac arrhythmias, including supraventricular tachycardia and atrial fibrillation/flutter. It works by inhibiting the influx of calcium ions through slow channels in myocardial and vascular smooth muscle cells, leading to relaxation of blood vessels, reduced heart workload, increased oxygen supply to the heart, and slowed electrical conduction through the atrioventricular node. This results in lowered blood pressure, relief from angina symptoms, and control of abnormal heart rhythms. Off-label uses include prevention of cluster headaches and migraine prophylaxis[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on verapamil.